ACM
RNAZ icon

AIGH Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

AIGH Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2
Closed -$1.42M – 56
2022
Q3 		$1.42M Hold
2
– – 0.44% 34
2022
Q2 		$1.62M Buy
+2
New +$3.22M 0.43% 31
2022
Q1 		– Sell
-2
Closed -$3.23M – 50
2021
Q4 		$3.23M Hold
2
– – 0.98% 27
2021
Q3 		$3.8M Buy
+2
New +$4.62M 0.8% 28

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIGH Capital Management's RNAZ Position: Q4 2022 in Review

AIGH Capital Management sold out of TransCode Therapeutics (RNAZ) in Q4 2022, closing a stake of 2 shares — an estimated $1.42M sold.

AIGH Capital Management first reported a position in RNAZ in Q3 2021 and held it in 4 quarters. The position peaked at $3.8M in Q3 2021. 0 funds tracked by Wall St. Rank hold RNAZ as of Q4 2022.

  • AIGH Capital Management reported no remaining TransCode Therapeutics position as of Q4 2022 after selling out during the quarter.
  • AIGH Capital Management sold 2 TransCode Therapeutics shares in Q4 2022, an estimated $1.42M.
  • AIGH Capital Management first reported a position in TransCode Therapeutics in Q3 2021 and held it in 4 quarters.
  • AIGH Capital Management's TransCode Therapeutics position peaked at $3.8M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2022.

Based on AIGH Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.